Oct 13, 2026 7:00 am EDT iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
Aug 28, 2026 7:00 am EDT iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Aug 4, 2026 7:00 am EDT iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
Jul 1, 2026 7:00 am EDT iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
Jun 2, 2026 7:00 am EDT iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
May 12, 2026 4:05 pm EDT iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
May 8, 2026 7:15 am EDT iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
Apr 8, 2026 7:00 am EDT iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia